< View all reports

Female Health Report

The female infertility market looks to increase, driven by many women's decisions to wait for pregnancy later in life 

Female infertility is defined as the inability to conceive a child after a period of 1 year of unprotected intercourse. This condition can be caused by many things and there are multiple forms of it. These forms include a diminished ovarian reserve, ovulation disorders, endometriosis, fallopian tube abnormalities, uterine factors, and unexpected infertility.

In this forecast report, GlobalData analyzes infertility in detail including epidemiology and etiology of this disorder. Although female infertility is gaining new treatments, challenges still remain to be explored.

  • What you will discover...
  • Understand the causes of female infertility and explore the pipeline treatments for this disorder
  • Assess market revenue and the annual cost of therapy allowing you to strategize for success
  • IVF success rates are a huge unmet need in this market and need to be improved
  • Although great progress has been made, KOLs interviewed by GlobalData emphasized that there is still room for the standard of care to improve

Female infertility drug market set to reach $2.5bn by 2028

The greatest drivers of growth in the global FI market are a growing number of women are postponing pregnancy until later in life and at a reproductively older age when fertility has generally decreased and the launch of Nolasiban in the US and 5EU, the first major innovation in this indication in many years.

Kelly Lambrinos, MA, Senior Pharma Analyst at GlobalData, explains:

“The fact that a growing number of women are postponing pregnancy until later in life when fertility has generally decreased, will translate into increased use of ART fertility treatments between 2018 and 2028.”

“A limited number of established companies compete in this space, and the strategy has mainly been to create improved versions of existing drugs. As such, the drugs used to treat patients have remained largely unchanged. These include, among others, blockbuster drugs such as EMD Serono’s Gonal-F (follitropin alfa), Merck & Co’s Follistim (follitropin beta) and Ferring Pharmaceuticals’ Menopur (menotropins) which collectively claimed over 50% of the total FI market in 2018.”

Non-surgical treatments, as well as treatments that can be administered less frequently, will be a key focus of this report. Gain in-depth knowledge of products in the pipeline and align your product plans accordingly.

Interested in dominating this market? Click ‘Buy Now’ to explore this report.

Purchase Today

Single user $ 10,995

Buy Now


+44 20 7947 2745

Not ready to buy yet? Download our free brochure on this report series

I consent to GlobalData collecting my details provided via this form.

You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our GlobalData Privacy Policy to see how we protect and manage your submitted data.